Literature DB >> 2009914

Cytosolic targeting of hen egg lysozyme gives rise to a short-lived protein presented by class I but not class II major histocompatibility complex molecules.

V Calin-Laurens1, F Forquet, E Mottez, J Kanellopoulos, F Godeau, P Kourilsky, D Gerlier, C Rabourdin-Combe.   

Abstract

A way to study the role of intracellular trafficking of an antigen in its presentation to T cells is to target the antigen to various cell compartments of the antigen-presenting cells (APC) and compare the nature of the complexes associating major histocompatibility complex (MHC) molecules and antigenic peptides, expressed on the cell surface. MHC class I+ and MHC class II+ mouse L fibroblasts secreting hen egg lysozyme (HELs cells) or expressing HEL in their cytosol (HELc cells) were obtained after transfection with HEL cDNA and signal sequence-deleted HEL cDNA, respectively. HEL was evidenced in both HELs- and HELc-transfected cells and the former type of transfectant secreted a large amount of HEL. However, HEL produced in the cytosol exhibited a short half-life of less than 5 min. HEL-derived peptides could not be shown biochemically either in HELc- nor in HELs-transfected cells. We then studied the capacity of these cells to present HEL to HEL-specific class I- and class II-restricted T cells. Both cell types could be recognized by the HEL-specific MHC class I-restricted CTL clones. In contrast, MHC class II-HEL peptide complexes, recognized by HEL-specific helper T cell hybridomas, could be detected on MHC class II+ HELs- but not HELc-transfected cells. In vivo experiments showed, however, that HELc-transfected cells could provide host APC with HELc-derived peptides able to associate with MHC class II molecules. This was inferred from the capacity of MHC class II-HELc-transfected cells, unable by themselves to elicit any anti-HEL antibody response, to prime syngeneic and allogeneic mice against HEL. The priming was revealed by the induction of an antibody response after a boost with an amount of HEL unable itself to elicit an antibody response.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2009914     DOI: 10.1002/eji.1830210332

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

1.  Presentation of a cytosolic antigen by major histocompatibility complex class II molecules requires a long-lived form of the antigen.

Authors:  M Guéguen; E O Long
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

Review 2.  Endogenous antigen presentation by MHC class II molecules.

Authors:  A J Sant
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

3.  Glycosyl-phosphatidylinositol-anchored and transmembrane forms of CD46 display similar measles virus receptor properties: virus binding, fusion, and replication; down-regulation by hemagglutinin; and virus uptake and endocytosis for antigen presentation by major histocompatibility complex class II molecules.

Authors:  G Varior-Krishnan; M C Trescol-Biémont; D Naniche; C Rabourdin-Combe; D Gerlier
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

4.  Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus.

Authors:  D Naniche; G Varior-Krishnan; F Cervoni; T F Wild; B Rossi; C Rabourdin-Combe; D Gerlier
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

5.  Measles virus transmembrane fusion protein synthesized de novo or presented in immunostimulating complexes is endogenously processed for HLA class I- and class II-restricted cytotoxic T cell recognition.

Authors:  R S van Binnendijk; C A van Baalen; M C Poelen; P de Vries; J Boes; V Cerundolo; A D Osterhaus; F G UytdeHaag
Journal:  J Exp Med       Date:  1992-07-01       Impact factor: 14.307

6.  Presentation of newly synthesized glycoproteins to CD4+ T lymphocytes. An analysis using influenza hemagglutinin transport mutants.

Authors:  D J Kittlesen; L R Brown; V L Braciale; J P Sambrook; M J Gething; T J Braciale
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

7.  Processing of a viral glycoprotein in the endoplasmic reticulum for class II presentation.

Authors:  S M Bartido; S Diment; C S Reiss
Journal:  Eur J Immunol       Date:  1995-08       Impact factor: 5.532

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.